On May 21, 2025 Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering the next generation of precision cancer medicines, reported that the first patient has been dosed in the TNG456 Phase 1/2 trial in patients with MTAP-deleted solid tumors, with a focus on glioblastoma (GBM). TNG456 is a next-generation, brain-penetrant, MTA-cooperative PRMT5 inhibitor.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Dosing the first patient in the TNG456 Phase 1/2 trial marks a significant step for us and for patients with MTAP-deleted GBM," said Adam Crystal, M.D., Ph.D., President, Research and Development of Tango Therapeutics. "People with GBM currently have few treatment options and a five-year survival rate below 10%. 45% of GBM is MTAP-deleted, thus a substantial number of patients have the potential to benefit from TNG456, where preclinical studies demonstrate potency, MTAP-selectivity and brain exposure that has the potential to be sufficient for meaningful efficacy in GBM."

The Phase 1/2 clinical trial (NCT06810544) is evaluating the safety, pharmacokinetics, pharmacodynamics and antitumor activity of TNG456 as a monotherapy and in combination with abemaciclib. We are currently enrolling patients with TNG456 monotherapy in dose escalation focused on GBM.

(Press release, Tango Therapeutics, MAY 21, 2025, View Source [SID1234662281])